Glycopyrrolate inhalation - Novartis

Drug Profile

Glycopyrrolate inhalation - Novartis

Alternative Names: AD-237; Enurev Breezhaler; Inhaled glycopyrrolate; Inhaled glycopyrronium bromide; NVA-237; Seebri Breezhaler; Seebri Inhalation Capsules; Seebri Neohaler; Tovanor Breezhaler

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Arakis Ltd; Vectura
  • Developer Novartis
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 10 Jan 2017 Venctura intends to market glycopyrrolate inhalation (Utibron™ Neohaler®) in the first half of 2017 in USA
  • 21 Dec 2016 Glycopyrrolate inhalation licensed to Sunovion Pharmaceuticals in USA
  • 19 Aug 2016 Novartis Pharmaceuticals withdraws a phase III trial for Chronic obstructive pulmonary disease in Brazil (NCT01837927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top